

TENET HEALTHCARE CORP  
Form 8-K  
June 25, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 25, 2014**

**TENET HEALTHCARE CORPORATION**

(Exact name of registrant as specified in its charter)

**Nevada**  
(State or other jurisdiction of  
incorporation)

**1-7293**  
(Commission File Number)

**95-2557091**  
(IRS Employer Identification No.)

**1445 Ross Avenue, Suite 1400, Dallas, Texas**  
(Address of principal executive offices)

**75202**  
(Zip Code)

Registrant's telephone number, including area code: **(469) 893-2200**

---

**Not Applicable**

## Edgar Filing: TENET HEALTHCARE CORP - Form 8-K

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-



Edgar Filing: TENET HEALTHCARE CORP - Form 8-K

The proceeds from the sale of the Notes will be used to redeem Tenet's 9.25% Senior Notes due 2015 and to pay related transaction fees and expenses.

**Item 9.01 Financial Statements and Exhibits**

(d) The following exhibits are filed as a part of this Report.

<b>Exhibit No.</b>	<b>Description</b>
4.1	Indenture, dated as of November 6, 2001, between Tenet and the Trustee (Incorporated by reference to Exhibit 4.1 to Tenet's Current Report on Form 8-K, dated November 6, 2001 and filed November 9, 2001).
4.2	Twenty-Third Supplemental Indenture, dated as of March 10, 2014, between Tenet and the Trustee (incorporated by reference to Exhibit 4.2 to Tenet's 8-K filed with the SEC on March 10, 2014).
10.1	Exchange and Registration Rights Agreement, dated as of June 25, 2014, between Tenet and Barclays Capital Inc., as representative of the initial purchasers.
99.1	Press release dated June 25, 2014, announcing closing of notes offering.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TENET HEALTHCARE CORPORATION

Date: June 25, 2014

By:	/s/ Paul A. Castanon	
	Name:	Paul A. Castanon
	Title:	Vice President, Deputy General Counsel and Corporate Secretary

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
4.1	Indenture, dated as of November 6, 2001, between Tenet and the Trustee (Incorporated by reference to Exhibit 4.1 to Tenet's Current Report on Form 8-K, dated November 6, 2001 and filed November 9, 2001).
4.2	Twenty-Third Supplemental Indenture, dated as of March 10, 2014, between Tenet and the Trustee (incorporated by reference to Exhibit 4.2 to Tenet's 8-K filed with the SEC on March 10, 2014).
10.1	Exchange and Registration Rights Agreement, dated as of June 25, 2014, between Tenet and Barclays Capital Inc., as representative of the initial purchasers.
99.1	Press release dated June 25, 2014, announcing closing of notes offering.